NR1H4 gene
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase
Actionable Insights Powered by AI
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase